Development of ERK1/2 inhibitors as a therapeutic strategy for tumour with MAPK upstream target mutations
- PMID: 31340679
- DOI: 10.1080/1061186X.2019.1648477
Development of ERK1/2 inhibitors as a therapeutic strategy for tumour with MAPK upstream target mutations
Abstract
Extracellular signal-regulated kinases 1 and 2 (ERK1/2) phosphorylate a variety of substrates that play key roles in promoting cell survival and proliferation. Many inhibitors, acting on upstream of the ERK pathway, exhibit excellent antitumor activity. However, drug-resistant tumour cells invariably emerge after their use due to the reactivation of ERK1/2 signalling. ERK1/2 inhibitors have shown clinical efficacy as a therapeutic strategy for the treatment of tumours with mitogen-activated protein kinase (MAPK) upstream target mutations. These inhibitors may be effective against cancers with altered MAPK upstream pathway and may be used as a possible strategy to overcome acquired resistance to MAPK inhibitors. In this review, we describe the mechanism and types of ERK1/2 inhibitors, summarise the current development status of small-molecule ERK1/2 inhibitors, including the preclinical data and clinical study progress, and discuss the future research directions for the application of ERK1/2 inhibitors.
Keywords: ERK1/2 inhibitors; MAPK pathway; clinical; drug resistant; preclinical; tumour.
Similar articles
-
Molecular Dynamics Simulations in Designing DARPins as Phosphorylation-Specific Protein Binders of ERK2.Molecules. 2021 Jul 27;26(15):4540. doi: 10.3390/molecules26154540. Molecules. 2021. PMID: 34361694 Free PMC article.
-
Progress in the development of ERK1/2 inhibitors for treating cancer and other diseases.Adv Pharmacol. 2024;100:181-207. doi: 10.1016/bs.apha.2024.04.001. Epub 2024 Apr 24. Adv Pharmacol. 2024. PMID: 39034052 Review.
-
ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy.Clin Cancer Res. 2018 Aug 15;24(16):4044-4055. doi: 10.1158/1078-0432.CCR-17-3674. Epub 2018 May 14. Clin Cancer Res. 2018. PMID: 29760222
-
Design, synthesis and biological evaluation of fused naphthofuro[3,2-c] quinoline-6,7,12-triones and pyrano[3,2-c]quinoline-6,7,8,13-tetraones derivatives as ERK inhibitors with efficacy in BRAF-mutant melanoma.Bioorg Chem. 2019 Feb;82:290-305. doi: 10.1016/j.bioorg.2018.10.044. Epub 2018 Oct 23. Bioorg Chem. 2019. PMID: 30396063 Free PMC article.
-
Intrinsic and acquired resistance to MEK1/2 inhibitors in cancer.Biochem Soc Trans. 2014 Aug;42(4):776-83. doi: 10.1042/BST20140129. Biochem Soc Trans. 2014. PMID: 25109957 Review.
Cited by
-
PIGNet: a physics-informed deep learning model toward generalized drug-target interaction predictions.Chem Sci. 2022 Feb 7;13(13):3661-3673. doi: 10.1039/d1sc06946b. eCollection 2022 Mar 30. Chem Sci. 2022. PMID: 35432900 Free PMC article.
-
Regulation of ERK2 activity by dynamic S-acylation.Cell Rep. 2023 Sep 26;42(9):113135. doi: 10.1016/j.celrep.2023.113135. Epub 2023 Sep 19. Cell Rep. 2023. PMID: 37715953 Free PMC article.
-
Homer1 promotes the conversion of A1 astrocytes to A2 astrocytes and improves the recovery of transgenic mice after intracerebral hemorrhage.J Neuroinflammation. 2022 Mar 14;19(1):67. doi: 10.1186/s12974-022-02428-8. J Neuroinflammation. 2022. PMID: 35287697 Free PMC article.
-
An injectable microparticle formulation for the sustained release of the specific MEK inhibitor PD98059: in vitro evaluation and pharmacokinetics.Drug Deliv Transl Res. 2021 Feb;11(1):182-191. doi: 10.1007/s13346-020-00758-9. Drug Deliv Transl Res. 2021. PMID: 32378175 Free PMC article.
-
Identification of potential extracellular signal-regulated protein kinase 2 inhibitors based on multiple virtual screening strategies.Front Pharmacol. 2022 Nov 18;13:1077550. doi: 10.3389/fphar.2022.1077550. eCollection 2022. Front Pharmacol. 2022. PMID: 36467098 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
